Annual EBIT
-$123.85 M
-$38.39 M-44.92%
December 31, 2024
Summary
- As of March 8, 2025, TCRX annual earnings before interest & taxes is -$123.85 million, with the most recent change of -$38.39 million (-44.92%) on December 31, 2024.
- During the last 3 years, TCRX annual EBIT has fallen by -$75.22 million (-154.70%).
- TCRX annual EBIT is now -771.54% below its all-time high of -$14.21 million, reached on December 31, 2019.
Performance
TCRX EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$35.02 M
-$6.10 M-21.07%
December 31, 2024
Summary
- As of March 8, 2025, TCRX quarterly earnings before interest & taxes is -$35.02 million, with the most recent change of -$6.10 million (-21.07%) on December 31, 2024.
- Over the past year, TCRX quarterly EBIT has dropped by -$16.26 million (-86.69%).
- TCRX quarterly EBIT is now -523.66% below its all-time high of -$5.62 million, reached on June 30, 2020.
Performance
TCRX Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$123.85 M
-$16.26 M-15.12%
December 31, 2024
Summary
- As of March 8, 2025, TCRX TTM earnings before interest & taxes is -$123.85 million, with the most recent change of -$16.26 million (-15.12%) on December 31, 2024.
- Over the past year, TCRX TTM EBIT has dropped by -$38.39 million (-44.92%).
- TCRX TTM EBIT is now -2097.41% below its all-time high of -$5.64 million, reached on March 31, 2020.
Performance
TCRX TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
TCRX EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -44.9% | -86.7% | -44.9% |
| 3 y3 years | -154.7% | -59.1% | -46.7% |
| 5 y5 years | -771.5% | -59.1% | -46.7% |
TCRX EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -154.7% | at low | -146.7% | at low | -154.6% | at low |
| 5 y | 5-year | -771.5% | at low | -523.7% | at low | -2097.4% | at low |
| alltime | all time | -771.5% | at low | -523.7% | at low | -2097.4% | at low |
TScan Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$123.85 M(+44.9%) | -$35.02 M(+21.1%) | -$123.85 M(+15.1%) |
| Sep 2024 | - | -$28.93 M(-5.8%) | -$107.58 M(+6.9%) |
| Jun 2024 | - | -$30.71 M(+5.2%) | -$100.67 M(+8.2%) |
| Mar 2024 | - | -$29.18 M(+55.6%) | -$93.03 M(+8.9%) |
| Dec 2023 | -$85.46 M(+31.4%) | -$18.76 M(-14.8%) | -$85.46 M(+1.2%) |
| Sep 2023 | - | -$22.02 M(-4.6%) | -$84.45 M(+7.6%) |
| Jun 2023 | - | -$23.08 M(+6.8%) | -$78.47 M(+11.3%) |
| Mar 2023 | - | -$21.61 M(+21.7%) | -$70.50 M(+8.4%) |
| Dec 2022 | -$65.05 M | -$17.75 M(+10.6%) | -$65.05 M(+5.8%) |
| Sep 2022 | - | -$16.04 M(+6.3%) | -$61.50 M(+0.3%) |
| Jun 2022 | - | -$15.10 M(-6.6%) | -$61.29 M(+7.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$16.16 M(+13.8%) | -$56.87 M(+16.9%) |
| Dec 2021 | -$48.63 M(+85.4%) | -$14.20 M(-10.3%) | -$48.64 M(+15.1%) |
| Sep 2021 | - | -$15.84 M(+48.3%) | -$42.25 M(+25.8%) |
| Jun 2021 | - | -$10.68 M(+34.9%) | -$33.58 M(+17.8%) |
| Mar 2021 | - | -$7.92 M(+1.4%) | -$28.52 M(+8.7%) |
| Dec 2020 | -$26.23 M(+84.6%) | - | - |
| Dec 2020 | - | -$7.81 M(+8.9%) | -$26.23 M(+42.4%) |
| Sep 2020 | - | -$7.17 M(+27.7%) | -$18.42 M(+63.7%) |
| Jun 2020 | - | -$5.62 M(-0.4%) | -$11.25 M(+99.6%) |
| Mar 2020 | - | -$5.64 M | -$5.64 M |
| Dec 2019 | -$14.21 M | - | - |
FAQ
- What is TScan Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for TScan Therapeutics?
- What is TScan Therapeutics annual EBIT year-on-year change?
- What is TScan Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for TScan Therapeutics?
- What is TScan Therapeutics quarterly EBIT year-on-year change?
- What is TScan Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for TScan Therapeutics?
- What is TScan Therapeutics TTM EBIT year-on-year change?
What is TScan Therapeutics annual earnings before interest & taxes?
The current annual EBIT of TCRX is -$123.85 M
What is the all time high annual EBIT for TScan Therapeutics?
TScan Therapeutics all-time high annual earnings before interest & taxes is -$14.21 M
What is TScan Therapeutics annual EBIT year-on-year change?
Over the past year, TCRX annual earnings before interest & taxes has changed by -$38.39 M (-44.92%)
What is TScan Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of TCRX is -$35.02 M
What is the all time high quarterly EBIT for TScan Therapeutics?
TScan Therapeutics all-time high quarterly earnings before interest & taxes is -$5.62 M
What is TScan Therapeutics quarterly EBIT year-on-year change?
Over the past year, TCRX quarterly earnings before interest & taxes has changed by -$16.26 M (-86.69%)
What is TScan Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of TCRX is -$123.85 M
What is the all time high TTM EBIT for TScan Therapeutics?
TScan Therapeutics all-time high TTM earnings before interest & taxes is -$5.64 M
What is TScan Therapeutics TTM EBIT year-on-year change?
Over the past year, TCRX TTM earnings before interest & taxes has changed by -$38.39 M (-44.92%)